DJIA 16,380.41 263.17 1.63%
NASDAQ 4,258.44 0.00 0.00%
S&P 500 1,886.76 24.00 1.29%
market minute promo

Eli Lilly & Co. (NYSE: LLY)

62.58 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

LLY $62.58 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $62.58
Daily Range $0.00 - $0.00
52-Week Range $48.88 - $67.14
Market Cap $69.9B
P/E Ratio 19.87
Dividend (Yield) $1.96 (3.1%)
Ex-Dividend Date
Dividend Pay Date
Volume 0
Average Daily Volume 4,203,744
Current FY EPS $2.77





Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website:

News & Commentary Rss Feed

Can Dividend Stock GlaxoSmithKline plc Bounce Back?

British pharma GlaxoSmithKline is being accused of corruption in yet another country, the United Arab Emirates. Given all the problems facing the company these days, can Glaxo turn things around?

Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations

XLV, MDT, LLY, AGN: Large Outflows Detected at ETF

Insider Trading Alert - LLY, ROSE And SCCO Traded By Insiders

Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues - Analyst Blog

Notable ETF Inflow Detected - IVE, WMT, LLY, MET

Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine And Cisplatin

The Most Important Number You Need to Know Before Buying Pfizer Inc. Stock

Every drugmaker faces a dangerous patent cliff, but Pfizer's (PFE) future growth is at stake if it can't develop new blockbusters to bridge the gap.

Why Is Sanofi Betting on MannKind Corporation's Afrezza?

Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?

5 States Expected to See the Biggest Increase in Alzheimer's Disease

Alzheimer's disease affects one in nine people age 65 and up, and is expected to be diagnosed in 13.8 million people in the U.S. by 2050. Find out which states are expected to see the biggest increase in diagnoses over the next decade, as well as what's being done to help fight this terrible disease.

See More LLY News...

LLY's Top Competitors

LLY $62.58 (0.00%)
Current stock: LLY
JNJ $98.70 (0.00%)
Current stock: JNJ
PFE $27.83 (0.00%)
Current stock: PFE
RHHBY $35.41 (0.00%)
Current stock: RHHBY